Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.

Researchers identify prognostic factors for elderly with chronic heart failure

10 Jan 2018

Researchers have identified prognostic factors associated with cardiovascular (CV) and non-CV mortality in elderly patients with chronic heart failure (CHF), and are calling for preventive measures to begin as early as the age of 65 years in patients with CHF. [Sato M, et al, AHA 2017, poster S5025]

A total of 4,876 patients with stage C/D CHF from the Japanese CHART-2 study were divided into three groups according to age (group 1, 64 years, n=1,521; group 2, 65–74 years, n=1,501; group 3, 75 years, n=1,845).

Overall, female patients had significantly lower non-CV mortality than male patients in group 2 (14.9 vs 21.8 percent; p=0.027) and group 3 (39.2 vs 55.9 percent; p<0.001). The proportion of non-CV death increased significantly after the age of 65 years in both males and females.

In patients <65 and 65 years of age, B-type natriuretic peptide (BNP) levels and history of stroke were associated with CV mortality, while BMI and history of cancer were associated with non-CV mortality.

Importantly, in patients 65 years of age, the researchers found additional factors associated with CV and non-CV mortality that were not prognostic in those aged <65 years. In these elderly patients, haemoglobin levels (hazard ratio [HR], 0.89; p<0.001) and history of hyperuricaemia (HR, 1.40; p=0.003) were associated with CV mortality, while haemoglobin levels (HR, 0.90; p=0.001), albumin levels (HR, 0.58; p<0.001), history of hyperuricaemia (HR, 1.35; p=0.006) and history of stroke (HR, 1.70; p<0.001) were associated with non-CV mortality.

“These results suggest that CHF management to prevent both CV and non-CV deaths should be initiated at least as early as the age of 65 years in the elderly,” the researchers concluded.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Pearl Toh, 13 Jan 2018
A study finds no evidence that using pharmaceutical aids alone for smoking cessation helps improve the chances of successful quitting despite promising results in previous randomized trials and routine prescription of such drugs to help quit smoking.
Elvira Manzano, 5 days ago
Cancer patients at risk for recurrent venous thromboembolism (VTE) are less likely to experience recurrence with rivaroxaban compared with dalteparin, the Select-D trial has shown, ushering in a new standard of care (SoC) for cancer-related VTE.
Yesterday
Rates of immunization particularly in a primary care setting can be improved by constant patient reminders and recall systems, a recent study has found.
Roshini Claire Anthony, 2 days ago

The combination of ceftazidime and avibactam proved noninferior to meropenem in adults with nosocomial pneumonia, positioning it as a potential treatment option for this condition, results from the phase III REPROVE* trial show. Nonetheless, the combination was associated with a higher number of safety events compared with meropenem.